Oral recombinant methioninase prevents nonalcoholic fatty liver disease in mice on a high fat diet

Yoshihiko Tashiro, Qinghong Han, Yuying Tan, Norihiko Sugisawa, Jun Yamamoto, Hiroto Nishino, Sachiko Inubushi, Yu Sun, Hyein Lim, Takeshi Aoki, Masahiko Murakami, Yoshihisa Takahashi, Michael Bouvet, Robert M. Hoffman

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Background/Aim: We have recently shown that oral recombinant methionase (o-rMETase) prevents obesity and diabetes onset in mice on a high-fat (HF) diet. The present study aimed to determine if o-rMETase can inhibit the onset of nonalcoholic fatty liver disease (NAFLD) onset in mice on a high-fat diet. Materials and Methods: Male C57BL/6J mice in the control group were fed a normal-fat diet (NFD) (+6.5% fat), and other mice were fed a high-fat (HF) diet (+34.3% fat). Then, the mice on the HF diet were divided into two dietary groups: i) HF+phosphate buffered saline (PBS) group, and ii) HF+o-rMETase group. Result: The fatty change score in the livers of mice treated with HF+PBS increased to an average of 2.6 during the experimental period of 8 weeks. In contrast, the fatty change in the livers of mice on the HF+o-rMETase group had an average score of 0.92 (p=0.04, HF+PBS vs HF+o-rMETase). Conclusion: o-rMETase inhibited the onset of NAFLD as well as prevented obesity and the onset of diabetes on a high-fat diet, offering a possibility of a new paradigm to prevent liver cirrhosis or liver cancer via NAFLD.

Original languageEnglish
Pages (from-to)979-984
Number of pages6
JournalIn Vivo
Issue number3
Publication statusPublished - 2020 Jun
Externally publishedYes


  • Fatty liver
  • MR
  • Methioninase
  • Methionine restriction
  • Mice

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology


Dive into the research topics of 'Oral recombinant methioninase prevents nonalcoholic fatty liver disease in mice on a high fat diet'. Together they form a unique fingerprint.

Cite this